[0014a]

In one aspect, the present invention provides a use of a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell in the manufacture of a cell product for treatment of epidermolysis bullosa, wherein said pluripotent stem cell shows non-expression for CD117, CD146, NG2, CD34, vWF and CD271.

[0015]

According to the present disclosure, Muse cells can be administered to a patient with epidermolysis bullosa via a blood vessel or the like, or directly to its skin site forming a blister or erosion and its periphery, to reconstruct and repair the damaged skin, thereby ameliorating or healing the skin symptoms. Thus, the cell product comprising Muse cells of the present disclosure can be used for treatment of epidermolysis bullosa.

CLAIMS

1. Use of a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell in the manufacture of a cell product for treatment of epidermolysis bullosa, wherein said pluripotent stem cell shows non-expression for CD117, CD146, NG2, CD34, vWF and CD271.

2. The use of claim 1, wherein said epidermolysis bullosa is epidermolysis bullosa simplex.

3. The use of claim 1, wherein said epidermolysis bullosa is junctional epidermolysis bullosa.

4. The use of claim 1, wherein said epidermolysis bullosa is dystrophic epidermolysis bullosa.

5. The use of claim 4, wherein said dystrophic epidermolysis bullosa is dominant dystrophic epidermolysis bullosa or recessive dystrophic epidermolysis bullosa.

6. The use of any one of claims 1 to 5, wherein said pluripotent stem cell has all of the following characteristics:

(i) having low or no telomerase activity;

(ii) capable of differentiating into any of tridermic cells;

(iii) showing no neoplastic proliferation; and

(iv) having self-renewal capacities.

7. The use of any one of claims 1 to 5, wherein said pluripotent stem cell has all of the following characteristics:

(i) SSEA-3 positive;

(ii) CD105 positive;

(iii) having low or no telomerase activity;

(iv) capable of differentiating into any of tridermic cells;

(v) showing no neoplastic proliferation; and

(vi) having self-renewal capacities.